Vasoactive intestinal peptide induces proliferation of human hepatocytes
© 2018 John Wiley & Sons Ltd..
OBJECTIVES: Proliferation of hepatocytes in vitro can be stimulated by growth factors such as epidermal growth factor (EGF), but the role of vasoactive intestinal peptide (VIP) remains unclear. We have investigated the effect of VIP on maintenance and proliferation of human hepatocytes.
MATERIALS AND METHODS: Human hepatocytes were isolated from liver specimens obtained from patients undergoing liver surgery. Treatment with VIP or EGF was started 24 h after plating and continued for 3 or 5 d. DNA replication was investigated by Bromodeoxyuridine (BrdU) incorporation and cell viability detected by MTT assay. Cell lysate was analysed by western blotting and RT-PCR. Urea and albumin secretion into the culture supernatants were measured.
RESULTS: VIP increased DNA replication in hepatocytes in a dose-dependant manner, with a peak response at day 3 of treatment. VIP treatment was associated with an increase in mRNA expression of antigen identified by monoclonal antibody Ki-67 (MKI-67) and Histone Cluster 3 (H3) genes. Western blotting analysis showed that VIP can induce a PKA/B-Raf dependant phosphorylation of extracellular signal-regulated kinases (ERK). Although EGF can maintain hepatocyte functions up to day 5, no marked efffect was found with VIP.
CONCLUSIONS: VIP induces proliferation of human hepatocytes with little or no effect on hepatocyte differentiation. Further investigation of the role of VIP is required to determine if it may ultimately support therapeutic approaches of liver disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Cell proliferation - 51(2018), 5 vom: 17. Okt., Seite e12482 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Khedr, M E M S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
37221-79-7 |
|---|
| Anmerkungen: |
Date Completed 01.10.2018 Date Revised 09.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/cpr.12482 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM28669025X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM28669025X | ||
| 003 | DE-627 | ||
| 005 | 20231225052318.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/cpr.12482 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0955.xml |
| 035 | |a (DE-627)NLM28669025X | ||
| 035 | |a (NLM)30028555 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Khedr, M E M S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vasoactive intestinal peptide induces proliferation of human hepatocytes |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.10.2018 | ||
| 500 | |a Date Revised 09.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2018 John Wiley & Sons Ltd. | ||
| 520 | |a OBJECTIVES: Proliferation of hepatocytes in vitro can be stimulated by growth factors such as epidermal growth factor (EGF), but the role of vasoactive intestinal peptide (VIP) remains unclear. We have investigated the effect of VIP on maintenance and proliferation of human hepatocytes | ||
| 520 | |a MATERIALS AND METHODS: Human hepatocytes were isolated from liver specimens obtained from patients undergoing liver surgery. Treatment with VIP or EGF was started 24 h after plating and continued for 3 or 5 d. DNA replication was investigated by Bromodeoxyuridine (BrdU) incorporation and cell viability detected by MTT assay. Cell lysate was analysed by western blotting and RT-PCR. Urea and albumin secretion into the culture supernatants were measured | ||
| 520 | |a RESULTS: VIP increased DNA replication in hepatocytes in a dose-dependant manner, with a peak response at day 3 of treatment. VIP treatment was associated with an increase in mRNA expression of antigen identified by monoclonal antibody Ki-67 (MKI-67) and Histone Cluster 3 (H3) genes. Western blotting analysis showed that VIP can induce a PKA/B-Raf dependant phosphorylation of extracellular signal-regulated kinases (ERK). Although EGF can maintain hepatocyte functions up to day 5, no marked efffect was found with VIP | ||
| 520 | |a CONCLUSIONS: VIP induces proliferation of human hepatocytes with little or no effect on hepatocyte differentiation. Further investigation of the role of VIP is required to determine if it may ultimately support therapeutic approaches of liver disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Ki-67 Antigen |2 NLM | |
| 650 | 7 | |a RNA, Messenger |2 NLM | |
| 650 | 7 | |a Vasoactive Intestinal Peptide |2 NLM | |
| 650 | 7 | |a 37221-79-7 |2 NLM | |
| 650 | 7 | |a Epidermal Growth Factor |2 NLM | |
| 650 | 7 | |a 62229-50-9 |2 NLM | |
| 650 | 7 | |a Mitogen-Activated Protein Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 700 | 1 | |a Abdelmotelb, A M |e verfasserin |4 aut | |
| 700 | 1 | |a Bedwell, T A |e verfasserin |4 aut | |
| 700 | 1 | |a Shtaya, A |e verfasserin |4 aut | |
| 700 | 1 | |a Alzoubi, M N |e verfasserin |4 aut | |
| 700 | 1 | |a Abu Hilal, M |e verfasserin |4 aut | |
| 700 | 1 | |a Khakoo, S I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell proliferation |d 1993 |g 51(2018), 5 vom: 17. Okt., Seite e12482 |w (DE-627)NLM013150766 |x 1365-2184 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2018 |g number:5 |g day:17 |g month:10 |g pages:e12482 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/cpr.12482 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2018 |e 5 |b 17 |c 10 |h e12482 | ||